Great Point Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Great Point Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-149,500	Closed	-$21.9M	–	45
2023 Q1	$21.9M	Sell	149,500 -10,500	-7%	-$1.55M	4.3%	10
2022 Q4	$25.5M	Sell	160,000 -55,000	-26%	-$8.06M	5%	6
2022 Q3	$28.7M	Buy	215,000 +25,000	+13%	+$3.8M	6.9%	2
2022 Q2	$29.6M	Buy	190,000 +35,000	+23%	+$5.39M	7.11%	2
2022 Q1	$24.1M	Buy	+155,000	New	+$22.5M	5.83%	5
2017 Q2	–	Sell	-25,000	Closed	-$3.63M	–	42
2017 Q1	$3.63M	Buy	+25,000	New	+$3.26M	0.72%	29

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Great Point Partners's JAZZ Position: Q2 2023 in Review

Great Point Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2023, closing a stake of 149,500 shares — an estimated $21.9M sold.

Great Point Partners first reported a position in JAZZ in Q1 2017 and held it in 6 quarters. The position peaked at $29.6M in Q2 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

Great Point Partners reported no remaining Jazz Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Great Point Partners sold 149,500 Jazz Pharmaceuticals shares in Q2 2023, an estimated $21.9M.
Great Point Partners first reported a position in Jazz Pharmaceuticals in Q1 2017 and held it in 6 quarters.
Great Point Partners's Jazz Pharmaceuticals position peaked at $29.6M in Q2 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Great Point Partners's 13F filing for Q2 2023, filed 14 Aug 2023.